Compare Cassava Sciences Inc (FLNA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Under Armour Inc Class A — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Under Armour Inc Class A trades at $7.12 (market cap $2.89B). The key difference: Under Armour Inc Class A is far larger — about 54.4× Cassava Sciences Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | UA | |
|---|---|---|
Market Cap | $53.14M | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $7.88 |
52-Week Low | $1.09 | $3.96 |
Enterprise Value | -$33.43M | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Under Armour (UA) trades at $7.04, up 8.81% with a bullish technical signal from moving averages and oscillators. The company reported mixed Q1 2026 results with a miss on EPS but maintains a 40.3% analyst buy rating. Recent news highlights a Dodge collaboration and significant insider buying by Fairfax Financial, though financials show negative net income margins and cash flow challenges with a net loss of $201.27 million in 2025.
The outlook is cautious due to declining revenue projections and profitability concerns, but potential exists from strategic partnerships and cost management. Key risks include sustained losses, competitive pressure, and macroeconomic headwinds. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
